Dataset Information


Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.

ABSTRACT: PURPOSE:The purpose of this study is to summarize the effectiveness and safety of metreleptin in patients with congenital or acquired generalized lipodystrophy. METHODS:Patients (n?=?66) aged ?6 months had lipodystrophy, low circulating leptin, and ?1 metabolic abnormality (diabetes mellitus, insulin resistance, or hypertriglyceridemia). Metreleptin dose (once or twice daily) was titrated to a mean dose of 0.10?mg/kg/day with a maximum of 0.24?mg/kg/day. Means and changes from baseline to month 12 were assessed for glycated hemoglobin (HbA1c), fasting triglycerides (TGs), and fasting plasma glucose (FPG). Additional assessments included the proportions of patients achieving target decreases in HbA1c or fasting TGs at months 4, 12, and 36, medication changes, and estimates of liver size. Treatment-emergent adverse events (TEAEs) were recorded. RESULTS:Significant mean reductions from baseline were seen at month 12 for HbA1c (-2.2%, n?=?59) and FPG (-3.0?mmol/L, n?=?59) and mean percent change in fasting TGs (-32.1%, n?=?57) (all p???0.001). Reductions from baseline over time in these parameters were also significant at month 36 (all p?


PROVIDER: S-EPMC5936645 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC7340120 | BioStudies
2016-01-01 | S-EPMC5026130 | BioStudies
2015-01-01 | S-EPMC4422900 | BioStudies
2019-01-01 | S-EPMC6563798 | BioStudies
2020-01-01 | S-EPMC7207763 | BioStudies
2019-01-01 | S-EPMC6676079 | BioStudies
2017-01-01 | S-EPMC5443330 | BioStudies
2018-01-01 | S-EPMC6063484 | BioStudies
2019-01-01 | S-EPMC6688455 | BioStudies
2011-01-01 | S-EPMC3498767 | BioStudies